Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review

Objectives Dyskeratosis congenita (DC) is a rare inherited disease characterized by the triad of reticulate hyperpigmentation, nail dystrophy and oral leukoplakia. DC patients are considered vulnerable to external pressure, such as immunochemotherapy. There are very few cases reporting severe therap...

Full description

Bibliographic Details
Main Authors: Jiayi Geng, Menglin Zhao, Qiuyu Li
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Hematology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2022.2120305
_version_ 1828407128171216896
author Jiayi Geng
Menglin Zhao
Qiuyu Li
author_facet Jiayi Geng
Menglin Zhao
Qiuyu Li
author_sort Jiayi Geng
collection DOAJ
description Objectives Dyskeratosis congenita (DC) is a rare inherited disease characterized by the triad of reticulate hyperpigmentation, nail dystrophy and oral leukoplakia. DC patients are considered vulnerable to external pressure, such as immunochemotherapy. There are very few cases reporting severe therapy-induced toxicities in patients with DC.Methods A 27-year-old woman was admitted to our hospital with a 4-month history of pancytopenia and a 7-day history of dyspnea with coughing. She was diagnosed with non-Hodgkin’s lymphoma 5 months ago. She received immunochemotherapy due to non-Hodgkin’s lymphoma but experienced recurrent fever, oral ulcer, pancytopenia, dyspnea and other symptoms during immunochemotherapy. On admission, she experienced an aggravation of respiratory symptoms, recurrent infections and acute heart failure.Results Laboratory examination confirmed pancytopenia, and chest computed tomography showed interstitial lung disease (ILD). Genetic analysis results confirmed the presence of DC and a TINF2 gene mutation. With continuous supportive and anti-infection treatment, her condition finally stabilized. She was discharged from the hospital after nearly 2 months.Discussion We reviewed similar cases and found common features that could be useful. However, the reported cases are very limited. More cases and studies are needed.Conclusion These cases indicate that DC patients seem more vulnerable to therapy toxicities; thus, physicians should be careful when treating these patients with chemotherapy drugs or radiation therapy. Reduced-intensity therapy may be considered.
first_indexed 2024-12-10T11:20:56Z
format Article
id doaj.art-b9e3c332efb7439fba83d4e5a6012e40
institution Directory Open Access Journal
issn 1607-8454
language English
last_indexed 2024-12-10T11:20:56Z
publishDate 2022-12-01
publisher Taylor & Francis Group
record_format Article
series Hematology
spelling doaj.art-b9e3c332efb7439fba83d4e5a6012e402022-12-22T01:50:56ZengTaylor & Francis GroupHematology1607-84542022-12-012711041104510.1080/16078454.2022.2120305Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature reviewJiayi Geng0Menglin Zhao1Qiuyu Li2Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People’s Republic of People’s Republic of ChinaDepartment of Cardiology, Peking University Third Hospital, Beijing, People’s Republic of People’s Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, People’s Republic of People’s Republic of ChinaObjectives Dyskeratosis congenita (DC) is a rare inherited disease characterized by the triad of reticulate hyperpigmentation, nail dystrophy and oral leukoplakia. DC patients are considered vulnerable to external pressure, such as immunochemotherapy. There are very few cases reporting severe therapy-induced toxicities in patients with DC.Methods A 27-year-old woman was admitted to our hospital with a 4-month history of pancytopenia and a 7-day history of dyspnea with coughing. She was diagnosed with non-Hodgkin’s lymphoma 5 months ago. She received immunochemotherapy due to non-Hodgkin’s lymphoma but experienced recurrent fever, oral ulcer, pancytopenia, dyspnea and other symptoms during immunochemotherapy. On admission, she experienced an aggravation of respiratory symptoms, recurrent infections and acute heart failure.Results Laboratory examination confirmed pancytopenia, and chest computed tomography showed interstitial lung disease (ILD). Genetic analysis results confirmed the presence of DC and a TINF2 gene mutation. With continuous supportive and anti-infection treatment, her condition finally stabilized. She was discharged from the hospital after nearly 2 months.Discussion We reviewed similar cases and found common features that could be useful. However, the reported cases are very limited. More cases and studies are needed.Conclusion These cases indicate that DC patients seem more vulnerable to therapy toxicities; thus, physicians should be careful when treating these patients with chemotherapy drugs or radiation therapy. Reduced-intensity therapy may be considered.https://www.tandfonline.com/doi/10.1080/16078454.2022.2120305Dyskeratosis congenitabone marrow failureinterstitial lung diseasenon-hodgkin lymphomatelomeretelomerase
spellingShingle Jiayi Geng
Menglin Zhao
Qiuyu Li
Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review
Hematology
Dyskeratosis congenita
bone marrow failure
interstitial lung disease
non-hodgkin lymphoma
telomere
telomerase
title Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review
title_full Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review
title_fullStr Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review
title_full_unstemmed Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review
title_short Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review
title_sort severe immunochemotherapy induced toxicities in a patient with dyskeratosis congenita and literature review
topic Dyskeratosis congenita
bone marrow failure
interstitial lung disease
non-hodgkin lymphoma
telomere
telomerase
url https://www.tandfonline.com/doi/10.1080/16078454.2022.2120305
work_keys_str_mv AT jiayigeng severeimmunochemotherapyinducedtoxicitiesinapatientwithdyskeratosiscongenitaandliteraturereview
AT menglinzhao severeimmunochemotherapyinducedtoxicitiesinapatientwithdyskeratosiscongenitaandliteraturereview
AT qiuyuli severeimmunochemotherapyinducedtoxicitiesinapatientwithdyskeratosiscongenitaandliteraturereview